Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study - Summary - MDSpire

Correction: The effect of dapagliflozin on cardiorespiratory fitness in patients with coronary heart disease and type 2 diabetes mellitus following PCI: a single-center prospective randomized controlled study

  • By

  • Jiali Yang

  • Xinru Li

  • Liangqiu Tang

  • Wenmao Fan

  • Aihua Li

  • Wanming Zhou

  • Jungang Pang

  • Qiuxiao Yuan

  • Ming Zhong

  • Jinhui Hou

  • Lan Wang

  • Wenjiao Liao

  • Xiangyang Liu

  • BMC Cardiovascular

  • June 2, 2026

  • 0 min

Share

Objective:

To correct inaccuracies in the data presented in the original article regarding the impact of Dapagliflozin, specifically detailing the nature of the inaccuracies.

Approach:
    Key Findings:
    • ACEI medication proportion in the Dapagliflozin group corrected from '8(10.03)' to '8(14.03)'
    • Nitrates proportion in the Non-dapagliflozin group corrected from '38(67.86)' to '27(48.21)'
    • BMI P-value corrected from '0.720' to '0.072'
    • Entries in Table 6 for Adjusted OR, 95% CI, and P were also corrected.
    Interpretation:

    Conclusion:

    Sources:

Original Source(s)

Related Content